JITC Best Paper Awards

The Journal for ImmunoTherapy of Cancer (JITC) Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts. Papers published in the 12 months leading up to the voting period were eligible for nomination for these awards.

JITC Best Basic Tumor Immunology Paper

Articles nominated in this category present research that covers tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, and other combination treatments with the antitumor immune response.

Laura Fernandez-Rodriguez, PhD

University of Basel and University Hospital of Basel

Chiara Cianciaruso, PhD

AGORA Cancer Research Center

“Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity”
Laura Fernandez-Rodriguez, Chiara Cianciaruso, Ruben Bill, Marcel P Trefny, Richard Klar, Nicole Kirchhammer, Mélanie Buchi, Julia Festag, Sven Michel, Rainer H Kohler, Elham Jones, Andre Maaske, Johannes vom Berg, Sebastian Kobold, Abhishek S Kashyap, Frank Jaschinski, Karen O Dixon, Mikael J Pittet, Alfred Zippelius
Journal for ImmunoTherapy of Cancer 2023;11:e006714 (19 May 2023) 

JITC Best Clinical/Translational Cancer Immunotherapy Paper

Articles nominated in this category present clinical research that has a clear potential to optimize patient care, with particular emphasis on high-quality randomized control trials, novel combination therapies, novel diagnostic or prognostic insights, and new insights into mechanisms of action.

Benny Johnson, DO

The University of Texas MD Anderson Cancer Center

“Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)”
Benny Johnson, Cara L Haymaker, Edwin R Parra, Luisa Maren Solis Soto, Xuemei Wang, Jane V Thomas, Arvind Dasari, Van K Morris, Kanwal Raghav, Eduardo Vilar, Bryan K Kee, Cathy Eng, Christine M Parseghian, Robert A Wolff, Younghee Lee, Daniele Lorenzini, Caddie Laberiano-Fernandez, Anuj Verma, Wenhua Lang, Ignacio I Wistuba, Andrew Futreal, Scott Kopetz, Michael J Overman

Journal for ImmunoTherapy of Cancer 2022;10:e005332 (25 August 2022)

JITC Best Immune Cell Therapies and Immune Cell Engineering Paper

Articles nominated in this category present research that discusses approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, and/or synthetic gene circuit.

Katherine P. Mueller, PhD

University of Wisconsin-Madison

Nicole J. Piscopo, PhD

University of Wisconsin-Madison

“Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression”
Katherine P Mueller, Nicole J Piscopo, Matthew H Forsberg, Louise A Saraspe, Amritava Das, Brittany Russell, Madeline Smerchansky, Dan Cappabianca, Lei Shi, Keerthana Shankar, Lauren Sarko, Namita Khajanchi, Nina La Vonne Denne, Apoorva Ramamurthy, Adeela Ali, Cicera R Lazzarotto, Shengdar Q Tsai, Christian M Capitini, Krishanu Saha

Journal for ImmunoTherapy of Cancer 2022;10:e004446 (7 September 2022)

JITC Best Immunotherapy Biomarkers Paper

Articles in this category present research that presents predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, and/or clinical trial analyses and identification of novel immune biomarkers.

Myrto K. Moutafi, MD

Yale University School of Medicine

Magdalena Molero-Abraham, PhD

Instituto de Investigación Hospital 12 de Octubre 

“Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer”
Myrto K Moutafi, Magdalena Molero, Sandra Martinez Morilla, Javier Baena, Ioannis A Vathiotis, Niki Gavrielatou, Laura Castro-Labrador, Gorka Ruiz de Garibay, Vera Adradas, Daniel Orive, Karmele Valencia, Alfonso Calvo, Luis M Montuenga, S Ponce Aix, Kurt A Schalper, Roy S Herbst, Luis Paz-Ares, David L Rimm, Jon Zugazagoitia

Journal for ImmunoTherapy of Cancer 2022;10:e004757 (24 August 2022)

JITC Best Oncolytic and Local Immunotherapy Paper

Articles nominated in this category present research that focuses on the role of therapeutic agents designed for targeting tumor cells and/or the tumor microenvironment. This includes oncolytic viruses, microbial agents, innate immune agonists, direct and systemically delivered proteins and DNA/RNA products that act within established tumors. Articles on translational and clinical investigation involving new oncolytic immunotherapy agents or those that include an oncolytic approach as part of combination therapeutic regimens are also represented.

Julia Katharina Schwarze, MD, MSc

Universitair Ziekenhuis

“Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial”
Julia Katharina Schwarze, Jens Tijtgat, Gil Awada, Louise Cras, Angela Vasaturo, Christopher Bagnall, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Bart Neyns

Journal for ImmunoTherapy of Cancer 2022;10:e005141 (16 September 22)

The Journal for ImmunoTherapy of Cancer (JITC) Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts. Papers published in the 12 months leading up to the voting period were eligible for nomination for these awards.

JITC Best Basic Tumor Immunology Paper

Papers nominated in this category present research that covers tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, and other combination treatments with the antitumor immune response.

JAMES MCAULIFFE, DPHIL

University of Oxford

“Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy”
James McAuliffe, Hok Fung Chan, Laurine Noblecourt, Ramiro Andrei Ramirez-Valdez, Vinnycius Pereira-Almeida, Yaxuan Zhou, Emily Pollock, Federica Cappuccini, Irina Redchenko, Adrian VS Hill, Carol Sze Ki Leung, Benoit J Van den Eynde

Journal for ImmunoTherapy of Cancer 2021;9:e003218 (2 September 2021)

JITC Best Clinical/Translational Cancer Immunotherapy Paper

Articles nominated in this category present clinical research that has a clear potential to optimize patient care, with particular emphasis on high-quality randomized control trials, novel combination therapies, novel diagnostic or prognostic insights, and new insights into mechanisms of action.

SHRUTI GUPTA, MD

Brigham and Women's Hospital

“Acute kidney injury in patients treated with immune checkpoint inhibitors”
Shruti Gupta, Samuel A P Short, Meghan E Sise, Jason M Prosek, Sethu M Madhavan, Maria Jose Soler, Marlies Ostermann, Sandra M Herrmann, Ala Abudayyeh, Shuchi Anand, Ilya Glezerman, Shveta S Motwani, Naoka Murakami, Rimda Wanchoo, David I Ortiz-Melo, Arash Rashidi, Ben Sprangers, Vikram Aggarwal, A Bilal Malik, Sebastian Loew, Christopher A Carlos, Wei-Ting Chang, Pazit Beckerman, Zain Mithani, Chintan V Shah, Amanda D Renaghan, Sophie De Seigneux, Luca Campedel, Abhijat Kitchlu, Daniel Sanghoon Shin, Sunil Rangarajan, Priya Deshpande, Gaia Coppock, Mark Eijgelsheim, Harish Seethapathy, Meghan D Lee, Ian A Strohbehn, Dwight H. Owen, Marium Husain, Clara Garcia-Carro, Sheila Bermejo, Nuttha Lumlertgul, Nina Seylanova, Lucy Flanders, Busra Isik, Omar Mamlouk, Jamie S Lin, Pablo Garcia, Aydin Kaghazchi, Yuriy Khanin, Sheru K Kansal, Els Wauters, Sunandana Chandra, Kai M Schmidt-Ott, Raymond K Hsu, Maria C Tio, Suraj Sarvode Mothi, Harkarandeep Singh, Deborah Schrag, Kenar D Jhaveri, Kerry L Reynolds, Frank B Cortazar, David E Leaf

Journal for ImmunoTherapy of Cancer 2021;9:e003467 (8 October 2021)

JITC Best Immune Cell Therapies and Immune Cell Engineering Paper

Papers nominated in this category present research that discusses approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, and/or synthetic gene circuit.

AMANI MAKKOUK, PHD, MS

Adicet Therapeutics

“Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma”
Amani Makkouk, Xue (Cher) Yang, Taylor Barca, Anthony Lucas, Mustafa Turkoz, Jonathan T S Wong, Kevin P Nishimoto, Mary M Brodey, Maryam Tabrizizad, Smitha R Y Gundurao, Lu Bai, Arun Bhat, Zili An, Stewart Abbot, Daulet Satpayev, Blake T Aftab, Marissa Herrman

Journal for ImmunoTherapy of Cancer 2021;9:e003441 (16 December 2021)

JITC Best Immunotherapy Biomarkers Paper

Articles in this category present research that presents predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, and/or clinical trial analyses and identification of novel immune biomarkers.

JINZHU MAO, PHD

Peking Union Medical College Hospital

DONGXU WANG, PHD

Peking Union Medical College Hospital

JUNYU LONG, PHD

Peking Union Medical College Hospital

XU YANG, PHD

Peking Union Medical College Hospital

“Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers”
Jinzhu Mao, Dongxu Wang, Junyu Long, Xu Yang, Jianzhen Lin, Yiwei Song, Fucun Xie, Ziyu Xun, Yanyu Wang, Yunchao Wang, Yiran Li, Huishan Sun, Jingnan Xue, Yang Song, Bangyou Zuo, Junwei Zhang, Jin Bian, Ting Zhang, Xiaobo Yang, Lei Zhang, Xinting Sang, Haitao Zhao

Journal for ImmunoTherapy of Cancer 2021;9:e003334 (6 December 2021)

JITC Best Oncolytic and Local Immunotherapy Paper

Papers nominated in this category present research that focuses on the role of therapeutic agents designed for targeting tumor cells and/or the tumor microenvironment. This includes oncolytic viruses, microbial agents, innate immune agonists, direct and systemically delivered proteins and DNA/RNA products that act within established tumors. Articles on translational and clinical investigation involving new oncolytic immunotherapy agents or those that include an oncolytic approach as part of combination therapeutic regimens are also represented.

MONIKA SEMMRICH, PHD

BioInvent International AB

JEAN-BAPTISTE MARCHAND, PHD

Transgene SA

“Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors”
Monika Semmrich, Jean-Baptiste Marchand, Laetitia Fend, Matilda Rehn, Christelle Remy, Petra Holmkvist, Nathalie Silvestre, Carolin Svensson, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Kirstie L Cleary, Mimoza Bodén, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Eric Quéméneur, Björn Frendéus

Journal for ImmunoTherapy of Cancer 2022;10:e003488 (19 January 22)

The Journal for ImmunoTherapy of Cancer (JITC) Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts. Papers published in the 12 months leading up to the voting period were eligible for nomination for these awards.

JITC Best Basic Tumor Immunology Paper

Papers nominated in this category present research that covers tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, and other combination treatments with the antitumor immune response.

Iuiliia Efimova

Ghent University

Elena Catanzaro, PhD

University of Bologna

“Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity”
Iuliia Efimova, Elena Catanzaro, Louis Van der Meeren, Victoria D Turubanova, Hamida Hammad, Tatiana A Mishchenko, Maria V Vedunova, Carmela Fimognari, Claus Bachert, Frauke Coppieters, Steve Lefever, Andre G Skirtach, Olga Krysko Dmitri V Krysko

Journal for ImmunoTherapy of Cancer 2020;8:e001369 (13 November 2020)

JITC Best Clinical/Translational Cancer Immunotherapy Paper

Articles nominated in this category present clinical research that has a clear potential to optimize patient care, with particular emphasis on high-quality randomized control trials, novel combination therapies, novel diagnostic or prognostic insights, and new insights into mechanisms of action.

Alessio Cortellini, MD

University of L'Aquila

“Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice”
Alessio Cortellini, Marco Tucci, Vincenzo Adamo, Luigia Stefania Stucci, Alessandro Russo, Enrica Teresa Tanda, Francesco Spagnolo, Francesca Rastelli, Renato Bisonni, Daniele Santini, Marco Russano, Cecilia Anesi, Raffaele Giusti, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Alain Gelibter, Mario Alberto Occhipinti, Riccardo Marconcini, Maria Giuseppa Vitale, Linda Nicolardi, Rita Chiari, Claudia Bareggi, Olga Nigro, Alessandro Tuzi, Michele De Tursi, Nicola Petragnani, Laura Pala, Sergio Bracarda, Serena Macrini, Alessandro Inno, Federica Zoratto, Enzo Veltri, Barbara Di Cocco, Domenico Mallardo, Maria Grazia Vitale, David James Pinato, Giampiero Porzio, Corrado Ficorella and Paolo Antonio Ascierto

Journal for ImmunoTherapy of Cancer 2020;8:e001361 (5 November 2020)

JITC Best Immune Cell Therapies and Immune Cell Engineering Paper

Papers nominated in this category present research that discusses approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, and/or synthetic gene circuit.

Kathrin Davari, PhD

Medigene Immunotherapies GmbH

Tristan Holland, PhD

Medigene Immunotherapies GmbH

“Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy”
Kathrin Davari, Tristan Holland, Laura Prassmayer, Giulia Longinotti, Kenneth P Ganley, Lisa J Pechilis, Iulia Diaconu, Prashant R Nambiar, Michael S Magee, Dolores J Schendel, Daniel Sommermeyer and Christian Ellinger

Journal for ImmunoTherapy of Cancer 2021;9:e002035 (25 March 2021)

JITC Best Immunotherapy Biomarkers Paper

Articles in this category present research that presents predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, and/or clinical trial analyses and identification of novel immune biomarkers.

Luca Cassetta, PhD

The Queen's Medical Research Institute, The University of Edinburgh

“Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation”
Luca Cassetta, Kirsten Bruderek, Joanna Skrzeczynska-Moncznik, Oktawia Osiecka, Xiaoying Hu, Ida Marie Rundgren, Ang Lin, Kim Santegoets, Utku Horzum, Ana Godinho-Santos, Gennadiy Zelinskyy, Thalia Garcia-Tellez, Sunčica Bjelica, Bartłomiej Taciak, Astrid Olsnes Kittang, Benedikt Höing, Stephan Lang, Michael Dixon, Verena Müller, Jochen Sven Utikal, Derya Karakoç, Kerim Bora Yilmaz, Emilia Górka, Lubomir Bodnar, Olympia Evdoxia Anastasiou, Christine Bourgeois, Robert Badura, Monika Kapinska-Mrowiecka, Mirjana Gotic, Mark ter Laan, Esther Kers-Rebel, Magdalena Król, Juan Francisco Santibañez, Michaela Müller-Trutwin, Ulf Dittmer, Ana Espada de Sousa, Güneş Esendağlı, Adema, Karin Loré, Elisabeth Ersvær, Viktor Umansky, Jeffrey W Pollard, Joanna Cichy and Sven Brandau

Journal for ImmunoTherapy of Cancer 2020;8:e001223 (8 September 2020)

JITC Best Oncolytic and Local Immunotherapy Paper

Papers nominated in this category present research that focuses on the role of therapeutic agents designed for targeting tumor cells and/or the tumor microenvironment. This includes oncolytic viruses, microbial agents, innate immune agonists, direct and systemically delivered proteins and DNA/RNA products that act within established tumors. Articles on translational and clinical investigation involving new oncolytic immunotherapy agents or those that include an oncolytic approach as part of combination therapeutic regimens are also represented.

Giulia Marelli, PhD

Queen Mary University of London

Louisa S Chard Dunmall, PhD

Queen Mary University of London

“A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer”
Giulia Marelli, Louisa S Chard Dunmall, Ming Yuan, Carmela Di Gioia, Jinxin Miao, Zhenguo Cheng, Zhongxian Zhang, Peng Liu, Jahangir Ahmed, Rathi Gangeswaran, Nicholas Lemoine and Yaohe Wang

Journal for ImmunoTherapy of Cancer 2021;9:e001624 (26 January 21)

The Journal for ImmunoTherapy of Cancer (JITC) Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts. Papers published in the 12 months leading up to the voting period were eligible for nomination for these awards.

JITC Best Basic Science Paper

Articles nominated in this category present innovative research in basic medical sciences that have a direct relevance to future research in clinical medicine.

Shuming Chen, PhD

John Hopkins University School of Medicine

"Mechanisms regulating PD-L1 expression on tumor and immune cells"
Shuming Chen, George A. Crabill, Theresa S. Pritchard, Tracee L. McMiller, Ping
Wei, Drew M. Pardoll, Fan Pan and Suzanne L. Topalian

Journal for ImmunoTherapy of Cancer 2019, 7:305 (15 November 2019)

JITC Best Clinical/Translational Paper

Papers in this category present clinical research that has a clear potential to optimize patient care, with particular emphasis on high quality randomized controlled trials, novel combination treatments, therapies, novel diagnostic or prognostic insights and new insights into mechanism of action.

Bryan D. Choi, md, phd

Massachusetts General Hospital

"CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma"
Bryan D. Choi, Xiaoling Yu, Ana P. Castano, Henia Darr, Daniel B. Henderson,
Amanda A. Bouffard, Rebecca C. Larson, Irene Scarfò, Stefanie R. Bailey,
Genevieve M. Gerhard, Matthew J. Frigault, Mark B. Leick, Andrea Schmidts,
Jason G. Sagert, William T. Curry, Bob S. Carter and Marcela V. Maus

Journal for ImmunoTherapy of Cancer 2019, 7:302 (14 November 2019)

JITC Best Basic Science Paper

Articles nominated in this category present innovative research in basic medical sciences that have a direct relevance to future research in clinical medicine.

Larissa S. Carnevalli, phd AstraZeneca	Charles Sinclair, phd Bristol-Myers Squibb

“PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity”
Larissa S. Carnevalli†, Charles Sinclair†, Molly A. Taylor, Pablo Morentin Gutierrez, Sophie Langdon, Anna M.L. Coenen-Stass, Lorraine Mooney, Adina Hughes, Laura Jarvis, Anna Staniszewska, Claire Crafter, Ben Sidders, Elizabeth Hardaker, Kevin Hudson, and Simon T. Barry
†Contributed equally

Journal for ImmunoTherapy of Cancer 2018, 6:109 (22 October 2018)

JITC Best Clinical/Translational Paper

Papers in this category present clinical research that has a clear potential to optimize patient care, with particular emphasis on high quality randomized controlled trials, novel combination treatments, therapies, novel diagnostic or prognostic insights and new insights into mechanism of action.

Asim amin, md, phd

Levine Cancer Institute

“Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study”
Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff, Lionel D. Lewis, Todd M. Bauer, David F. McDermott, Michael Carducci, Christian Kollmannsberger, Brian I. Rini, Daniel Y.C. Heng, Jennifer Knox, Martin H. Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J. Hammers

Journal for ImmunoTherapy of Cancer 2018, 6:109 (22 October 2018)

JITC Best Basic Science Paper

Articles nominated in this category present innovative research in basic medical sciences that have a direct relevance to future research in clinical medicine.

Patrick Danaher, PhD

NanoString Technologies

“Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)”

Patrick Danaher, Sarah Warren, Rongze Lu, Josue Samayoa, Amy Sullivan, Irena Pekker, Brett Wallden, Francesco M. Marincola, and Alessandra Cesano

Journal for ImmunoTherapy of Cancer 2018, 6:63 (22 June 2018)

JITC Best Clinical/Translational Paper

Papers in this category present clinical research that has a clear potential to optimize patient care, with particular emphasis on high quality randomized controlled trials, novel combination treatments, therapies, novel diagnostic or prognostic insights and new insights into mechanism of action.

Howard L. Kaufman, MD, FACS

Replimune Group

“Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials”
Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov, and Merrick Ross

Journal for ImmunoTherapy of Cancer 2017, 5:72 (19 September 2017)

The Journal for ImmunoTherapy of Cancer (JITC) Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts. Papers published in the last 12 months authored by Society for Immunotherapy of Cancer (SITC) members were eligible for nomination for this award.

JITC Best Basic Science Paper

Genevieve M. Weir, PhD

ImmunoVaccine

“Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide”

Genevieve M. Weir, Olga Hrytsenko, Tara Quinton, Neil L. Berinstein, Marianne M. Stanford and Marc Mansour

Journal for ImmunoTherapy of Cancer 2016, 4:68 (18 October 2016)

JITC Best Clinical/Translational Paper

Kristen M. Hege, MD

Celgene

“Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer”

Kristen M. Hege, Emily K. Bergsland, George A. Fisher, John J. Nemunaitis, Robert S. Warren, James G. McArthur, Andy A. Lin, Jeffrey Schlom, Carl H. June and Stephen A. Sherwin

Journal for ImmunoTherapy of Cancer 2017, 5:22 (21 March 2017)

The Journal for ImmunoTherapy of Cancer (JITC) Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts. Papers published in the last 12 months authored by Society for Immunotherapy of Cancer (SITC) members were eligible for nomination for this award.

JITC Best Basic Science Paper

Articles nominated in this category present innovative research in basic medical sciences that have a direct relevance to future research in clinical medicine.

Katherine Woods, PhD
Olivia Newton-John Cancer Research Institute

"Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma"
Katherine Woods, Ashley J. Knights, Matthew Anaka, Ralf B. Schittenhelm, Anthony W. Purcell, Andreas Behren and Jonathan Cebon

Journal for ImmunoTherapy of Cancer 2016 4:10

JITC Best Clinical/Translational Paper

Papers in this category present clinical research that has a clear potential to optimize patient care, with particular emphasis on high quality randomized controlled trials, novel combination treatments, therapies, novel diagnostic or prognostic insights and new insights into mechanism of action.

Zipei Feng Oregon Health & Science University	Sachin Puri, PhD MedImmune

"Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma"
Zipei Feng†, Sachin Puri†, Tarsem Moudgil, William Wood, Clifford C. Hoyt, Chichung Wang, Walter J. Urba, Brendan D. Curti, Carlo B. Bifulco and Bernard A. Fox
†Contributed equally

Journal for ImmunoTherapy of Cancer 2015 3:4

The Journal for ImmunoTherapy of Cancer (JITC) Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts. Papers published in the last 12 months authored by Society for Immunotherapy of Cancer (SITC) members were eligible for nomination for this award.

JITC Best Basic Science Paper

Articles nominated in this category present innovative research in basic medical sciences that have a direct relevance to future research in clinical medicine.

Weiqing Jing, MD
Medical College of Wisconsin

“Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma”
Weiqing Jing, Jill A. Gershan, James Weber, Dominique Tlomak, Laura McOlash, Catherine Sabatos-Peyton, Bryon D. Johnson

Journal for Immunotherapy of Cancer 2015, 3:2

JITC Best Clinical/Translational Paper

Papers in this category present clinical research that has a clear potential to optimize patient care, with particular emphasis on high quality randomized controlled trials, novel combination treatments, therapies, novel diagnostic or prognostic insights and new insights into mechanism of action.

Saskia Santegoets, PhD
VU University Medical Center Cancer Center Amsterdam

“Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab”
Saskia Santegoets, Anita Stam, Sinéad M. Lougheed, Helen Gall, Karin Jooss, Natalie Sacks, Kristen Hege, Israel Lowy, Rik J. Scheper, Winald R. Gerritsen, Alfons van den Eertwegh, Tanja D. de Gruijl

Journal for Immunotherapy of Cancer 2014, 2:31

The Journal for ImmunoTherapy of Cancer (JITC) Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts. Papers published in the last 12 months authored by Society for Immunotherapy of Cancer (SITC) members were eligible for nomination for this award.

JITC Best Basic Science Paper

Articles nominated in this category present innovative research in basic medical sciences that have a direct relevance to future research in clinical medicine.

Stefani Spranger, PhD
University of Chicago

"Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment"
Stefani Spranger, Holly K. Koblish, Brendan Horton, Peggy A. Scherle, Robert Newton and Thomas F. Gajewski

Journal for ImmunoTherapy of Cancer 2014 2:3

JITC Best Clinical/Translational Paper

Papers in this category present clinical research that has a clear potential to optimize patient care, with particular emphasis on high quality randomized controlled trials, novel combination treatments, therapies, novel diagnostic or prognostic insights and new insights into mechanism of action.

Shailender Bhatia, MD
University of Washington

"Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase I/II study"
Shailender Bhatia, Brendan Curti, Marc S. Ernstoff, Michael Gordon, Elisabeth I. Heath, Wilson H. Miller Jr., Igor Puzanov, David I. Quinn, Thomas W. Flaig, Peter VanVeldhuizen, Kelly Byrnes-Blake, Jeremy A. Freeman, Rachel Bittner, Naomi Hunder, Sonia Souza and John A. Thompson

Journal for ImmunoTherapy of Cancer 2014 2:2